Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.
Azimi A, Caramuta S, Seashore-Ludlow B, Boström J, Robinson JL, Edfors F, Tuominen R, Kemper K, Krijgsman O, Peeper DS, Nielsen J, Hansson J, Egyhazi Brage S, Altun M, Uhlen M, Maddalo G.
Azimi A, et al. Among authors: nielsen j.
Mol Syst Biol. 2018 Mar 5;14(3):e7858. doi: 10.15252/msb.20177858.
Mol Syst Biol. 2018.
PMID: 29507054
Free PMC article.